- Home
- HLP vs TARA Comparison
HLP vs TARA Comparison
Compare HLP & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- TARA
- Stock Information
- Founded
- HLP 2021
- TARA N/A
- Country
- HLP China
- TARA United States
- Employees
- HLP N/A
- TARA N/A
- Industry
- HLP Industrial Machinery/Components
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLP Industrials
- TARA Health Care
- Exchange
- HLP Nasdaq
- TARA Nasdaq
- Market Cap
- HLP 102.1M
- TARA 118.1M
- IPO Year
- HLP 2023
- TARA N/A
- Fundamental
- Price
- HLP $1.62
- TARA $5.07
- Analyst Decision
- HLP
- TARA Strong Buy
- Analyst Count
- HLP 0
- TARA 6
- Target Price
- HLP N/A
- TARA $19.80
- AVG Volume (30 Days)
- HLP 249.9K
- TARA 731.6K
- Earning Date
- HLP 09-19-2025
- TARA 11-11-2025
- Dividend Yield
- HLP N/A
- TARA N/A
- EPS Growth
- HLP N/A
- TARA N/A
- EPS
- HLP 0.02
- TARA N/A
- Revenue
- HLP $16,731,357.00
- TARA N/A
- Revenue This Year
- HLP N/A
- TARA N/A
- Revenue Next Year
- HLP N/A
- TARA N/A
- P/E Ratio
- HLP $70.09
- TARA N/A
- Revenue Growth
- HLP 19.13
- TARA N/A
- 52 Week Low
- HLP $0.61
- TARA $1.60
- 52 Week High
- HLP $1.82
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- HLP 76.04
- TARA 74.50
- Support Level
- HLP $1.30
- TARA $4.81
- Resistance Level
- HLP $1.53
- TARA $5.12
- Average True Range (ATR)
- HLP 0.14
- TARA 0.35
- MACD
- HLP 0.03
- TARA 0.10
- Stochastic Oscillator
- HLP 89.83
- TARA 86.70
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).